01/28/16 - 08:45 AM EST
Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.
01/27/16 - 11:41 AM EST
The controversy over drug pricing factored into Biogen's revenue guidance for 2016.
01/26/16 - 11:15 AM EST
Juno and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing an off-the-shelf, engineered T-cell therapy could induce remissions in patients with blood cancers.
01/25/16 - 01:03 PM EST
Biotech news and observations to start the week.
01/24/16 - 02:00 PM EST
Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.
01/24/16 - 11:00 AM EST
TheStreet's Adam Feuerstein responds to reader questions about Sarepta and its Duchenne muscular dystrophy drug eteplirsen.
01/21/16 - 08:27 AM EST
Alkermes said Thursday the experimental drug ALKS 5461 failed to improve depressive symptoms in patients with hard-to-treat depression, based on negative results from two late-stage clinical trials.
01/19/16 - 07:19 AM EST
Acorda's all-cash tender offer values Biotie at $363 million, or $25.60 per ADS, representing a 96% premium over the stock's closing price on Friday.
01/15/16 - 12:25 PM EST
The FDA's review team appears to cast significant doubt on eteplirsen's approval chances.
01/13/16 - 12:29 PM EST
Nothing at the J.P. Morgan Healthcare Conference is convincing health care investors to step up and buy biotech stocks.